Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
HIV Infections
Interventions
DRUG

Dapivirine Vaginal Ring

dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days

DRUG

Maraviroc Vaginal Ring

dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days

OTHER

Placebo Vaginal Ring

dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days

DRUG

Dapivirine-Maraviroc Vaginal Ring

dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days

Trial Locations (3)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

35294

University of Alabama at Birmingham, Birmingham

02115

The Fenway Institute/Fenway Community Health, Boston

All Listed Sponsors
lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT01363037 - Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring | Biotech Hunter | Biotech Hunter